Home » Stocks » Viela Bio

Viela Bio, Inc. (VIE)

Stock Price: $43.15 USD -1.05 (-2.38%)
Updated Jul 7, 2020 9:32 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.36B
Revenue (ttm) 50.00M
Net Income (ttm) n/a
Shares Out 51.00M
EPS (ttm) -103.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 7, 2020
Last Price $43.15
Previous Close $44.20
Change ($) -1.05
Change (%) -2.38%
Day's Open -
Day's Range 43.15 - 43.15
Day's Volume 1,301
52-Week Range 18.20 - 70.66

More Stats

Market Cap 2.36B
Enterprise Value 2.04B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 51.00M
Float 16.78M
EPS (basic) n/a
EPS (diluted) -103.07
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 878,446
Short Ratio 1.81
Short % of Float 4.30%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 47.12
PB Ratio 7.45
Revenue 50.00M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 314.83M
Net Cash / Share 5.77
Gross Margin 100.00%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -21.40%
ROE -48.26%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 5
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(46.00% upside)
Current: 43.15
Target: 63.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit50.00-
Operating Income-89.69-192
Net Income-86.43-190
Shares Outstanding12.31-
Earnings Per Share-7.02-19,027,000.00
Operating Cash Flow-105-29.53
Capital Expenditures-1.10-0.49
Free Cash Flow-106-30.02
Cash & Equivalents315127
Net Cash / Debt315127
Book Value355-188
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Viela Bio, Inc.
Country United States
Employees 147
CEO Zheng Bin Yao

Stock Information

Ticker Symbol VIE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VIE


Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.